{"id":48651,"date":"2025-11-19T20:55:40","date_gmt":"2025-11-19T12:55:40","guid":{"rendered":"https:\/\/flcube.com\/?p=48651"},"modified":"2025-11-19T20:55:41","modified_gmt":"2025-11-19T12:55:41","slug":"cutias-cu-40105-topical-finasteride-spray-nda-accepted-by-nmpa-a-china-first","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48651","title":{"rendered":"Cutia&#8217;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First"},"content":{"rendered":"\n<p><strong>Cutia Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2487:HKG\">HKG: 2487<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its New Drug Application (NDA) for <strong>CU\u201140105<\/strong>, a topical finasteride spray for the treatment of <strong>androgenetic alopecia<\/strong>, positioning it as the <strong>first and only topical finasteride product<\/strong> in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>CU\u201140105 (topical finasteride spray)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Cutia Therapeutics<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>NDA acceptance<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Androgenetic alopecia (male pattern hair loss)<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>First and only topical finasteride in China<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved in overseas markets; imported original product<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Technical review process; potential approval H2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Competitive inhibitor of <strong>Type II 5\u2011alpha reductase<\/strong>, blocking conversion of testosterone to dihydrotestosterone (DHT) in scalp tissue<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>Topical spray administration<\/strong> directly to scalp reduces <strong>systemic exposure by ~90%<\/strong> compared to oral finasteride, potentially minimizing systemic side effects<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Ready\u2011to\u2011use spray for targeted delivery to affected scalp areas<\/li>\n\n\n\n<li><strong>Patient Convenience:<\/strong> Avoids daily oral dosing and associated concerns about sexual dysfunction and mood changes (reported in 3\u20115% of oral finasteride users)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Alopecia Market (2024)<\/strong><\/td><td>\u00a58.5\u202fbillion (US$1.2\u202fbillion)<\/td><\/tr><tr><td><strong>Male Androgenetic Alopecia Patients<\/strong><\/td><td>&gt;30\u202fmillion men in China<\/td><\/tr><tr><td><strong>Oral Finasteride Market Share<\/strong><\/td><td>~35% of prescription alopecia treatments<\/td><\/tr><tr><td><strong>Peak Sales Forecast (CU\u201140105)<\/strong><\/td><td>\u00a51.5\u20112.0\u202fbillion (US$200\u2011270\u202fmillion) by 2030<\/td><\/tr><tr><td><strong>Market Capture Assumption<\/strong><\/td><td>15\u201120% of finasteride\u2011eligible patients switching to topical<\/td><\/tr><tr><td><strong>Price Premium<\/strong><\/td><td>Expected 30\u201140% premium vs. oral generic finasteride<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Landscape:<\/strong> Oral finasteride generics dominate; topical minoxidil is the only other topical prescription option. CU\u201140105 offers a <strong>first\u2011in\u2011class topical anti\u2011androgen<\/strong> alternative.<\/li>\n\n\n\n<li><strong>Physician Adoption:<\/strong> Dermatologists report strong interest in topical options to address patient concerns about systemic side effects; key opinion leader endorsements expected post\u2011launch.<\/li>\n\n\n\n<li><strong>Reimbursement:<\/strong> Likely self\u2011pay category initially; potential for inclusion in outpatient pharmacy benefits if real\u2011world safety data demonstrate clear advantage.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CU\u201140105\u2019s regulatory review timeline, market adoption, and revenue potential. Actual results may differ materially due to risks including NMPA approval outcomes, competitive responses, and physician uptake rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111900002_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025111900002_c.\"><\/object><a id=\"wp-block-file--media-0c793cac-2910-4d7f-86de-2d0f404c16ff\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111900002_c.pdf\">2025111900002_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111900002_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0c793cac-2910-4d7f-86de-2d0f404c16ff\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48653,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[450,1221,38],"class_list":["post-48651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cutia-therapeutics","tag-hkg-2487","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cutia&#039;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutia&#039;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First\" \/>\n<meta property=\"og:description\" content=\"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48651\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T12:55:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-19T12:55:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cutia&#8217;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First\",\"datePublished\":\"2025-11-19T12:55:40+00:00\",\"dateModified\":\"2025-11-19T12:55:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651\"},\"wordCount\":349,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1904.webp\",\"keywords\":[\"Cutia Therapeutics\",\"HKG: 2487\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48651#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48651\",\"name\":\"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1904.webp\",\"datePublished\":\"2025-11-19T12:55:40+00:00\",\"dateModified\":\"2025-11-19T12:55:41+00:00\",\"description\":\"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1904.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutia&#8217;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First - Insight, China&#039;s Pharmaceutical Industry","description":"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48651","og_locale":"en_US","og_type":"article","og_title":"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First","og_description":"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.","og_url":"https:\/\/flcube.com\/?p=48651","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-19T12:55:40+00:00","article_modified_time":"2025-11-19T12:55:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48651#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48651"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cutia&#8217;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First","datePublished":"2025-11-19T12:55:40+00:00","dateModified":"2025-11-19T12:55:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48651"},"wordCount":349,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","keywords":["Cutia Therapeutics","HKG: 2487","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48651#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48651","url":"https:\/\/flcube.com\/?p=48651","name":"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48651#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","datePublished":"2025-11-19T12:55:40+00:00","dateModified":"2025-11-19T12:55:41+00:00","description":"Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for CU\u201140105, a topical finasteride spray for the treatment of androgenetic alopecia, positioning it as the first and only topical finasteride product in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48651#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","width":1080,"height":608,"caption":"Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cutia&#8217;s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48651"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48651\/revisions"}],"predecessor-version":[{"id":48654,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48651\/revisions\/48654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48653"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}